Cingulate Inc., a biopharmaceutical company, has filed an Amendment No. 2 to FORM S-1 with the Securities and Exchange Commission (SEC) on October 7, 2024, for a Registration Statement under the Securities Act of 1933. This filing pertains to the registration of 1,500,000 shares of common stock to be offered and sold by the selling stockholder, Lincoln Park Capital Fund, LLC. The shares may be sold at market prices or at negotiated prices, and the selling stockholder may use an unaffiliated broker-dealer to facilitate sales. The proceeds from the sale of the shares will not go to Cingulate Inc., as the offering is by the selling stockholder. However, Cingulate Inc. may receive up to $4,713,220.68 from the sale of shares to Lincoln Park under a separate Purchase Agreement. The company's common stock and warrants are listed on the Nasdaq Capital Market under the symbols 'CING' and 'CINGW' respectively. The registration statement includes details about the company's business, the offering, and the use of proceeds, among other information.

Cingulate Inc., a biopharmaceutical company, has filed an Amendment No. 2 to FORM S-1 with the Securities and Exchange Commission (SEC) on October 7, 2024, for a Registration Statement under the Securities Act of 1933. This filing pertains to the registration of 1,500,000 shares of common stock to be offered and sold by the selling stockholder, Lincoln Park Capital Fund, LLC. The shares may be sold at market prices or at negotiated prices, and the selling stockholder may use an unaffiliated broker-dealer to facilitate sales. The proceeds from the sale of the shares will not go to Cingulate Inc., as the offering is by the selling stockholder. However, Cingulate Inc. may receive up to $4,713,220.68 from the sale of shares to Lincoln Park under a separate Purchase Agreement. The company's common stock and warrants are listed on the Nasdaq Capital Market under the symbols 'CING' and 'CINGW' respectively. The registration statement includes details about the company's business, the offering, and the use of proceeds, among other information.